SeaStar Medical Holding Corp has announced impressive financial results for the third quarter of 2026, showcasing a significant increase in revenue and notable advancements in its clinical trials. This update is crucial for the company as it highlights the effectiveness of its QUELIMMUNE therapy in treating critically ill patients, particularly those with acute kidney injury.
On November 11, 2026, SeaStar released its earnings report, revealing a remarkable 247% increase in net revenue compared to the same period last year. The surge in revenue is attributed to the continued adoption of the QUELIMMUNE therapy, which has been gaining traction in the medical community. The company also reported that it achieved nearly 75% enrollment in its pivotal NEUTRALIZE-AKI clinical trial, which focuses on adult patients undergoing continuous renal replacement therapy (CRRT).
SeaStar Medical Holding Corp operates within the surgical and medical instruments and apparatus sector, classified under SIC code 3841. The company is listed on the Nasdaq under the ticker symbols ICU and ICUCW. Recent filings indicate that SeaStar is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company.
The SEC filing, accession number 0001437749-26-036383, details the results of operations and financial condition for the three and nine months ended September 30, 2026. The company hosted a webcast on the same day to discuss its financial performance and operational updates, which will be available for three months following the event.
SeaStar's press release emphasized the positive outcomes of its QUELIMMUNE therapy, stating that it reported statistically significant higher survival rates for patients treated with QUELIMMUNE compared to those in the comparator cohort. This finding was presented at the ASN Kidney Week 2026, further establishing the therapy's credibility in the medical field.
The filing also mentions that SeaStar has fulfilled FDA post-approval requirements for its SAVE Registry study, which is a critical step in ensuring the therapy's continued compliance and marketability.
This update is likely to have a significant impact on various stakeholders, including investors, healthcare providers, and patients. Investors may view the substantial revenue growth and clinical advancements as a positive indicator of the company's future potential. Healthcare providers may be encouraged to adopt QUELIMMUNE therapy in their practice, given its promising clinical results. Patients suffering from acute kidney injury may benefit from the advancements in treatment options offered by SeaStar.
Looking ahead, SeaStar Medical is expected to continue its efforts in clinical trials and product development. The filing does not specify any upcoming votes or additional filings, but the company's trajectory suggests ongoing engagement with the medical community and regulatory bodies.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










